Advisory Alpha’s Edwards Lifesciences EW Stock Holding History

Advisory Alpha’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-27	Closed	-$2.02K	–	808
2019 Q3	$2.02K	Buy	+27	New	+$1.9K	﹤0.01%	648
2019 Q2	–	Sell	-9	Closed	-$544	–	277
2019 Q1	$544	Buy	+9	New	+$514	﹤0.01%	658

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Advisory Alpha's EW Position: Q4 2019 in Review

Advisory Alpha sold out of Edwards Lifesciences (EW) in Q4 2019, closing a stake of 27 shares — an estimated $2.02K sold.

Advisory Alpha first reported a position in EW in Q1 2019 and held it in 2 quarters. The position peaked at $2.02K in Q3 2019. 1,092 funds tracked by Wall St. Rank hold EW as of Q4 2019.

Advisory Alpha reported no remaining Edwards Lifesciences position as of Q4 2019 after selling out during the quarter.
Advisory Alpha sold 27 Edwards Lifesciences shares in Q4 2019, an estimated $2.02K.
Advisory Alpha first reported a position in Edwards Lifesciences in Q1 2019 and held it in 2 quarters.
Advisory Alpha's Edwards Lifesciences position peaked at $2.02K in Q3 2019.
1,092 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2019.

Based on Advisory Alpha's 13F filing for Q4 2019, filed 14 Feb 2020.